KR910001041A - 지효성의 히루딘 유도체 - Google Patents

지효성의 히루딘 유도체 Download PDF

Info

Publication number
KR910001041A
KR910001041A KR1019890007560A KR890007560A KR910001041A KR 910001041 A KR910001041 A KR 910001041A KR 1019890007560 A KR1019890007560 A KR 1019890007560A KR 890007560 A KR890007560 A KR 890007560A KR 910001041 A KR910001041 A KR 910001041A
Authority
KR
South Korea
Prior art keywords
hirudin
lys
derivative according
derivatives
carrier
Prior art date
Application number
KR1019890007560A
Other languages
English (en)
Other versions
KR0140884B1 (ko
Inventor
크라우세 페터
하베르만 파울
크라머 마르틴
오베르마이어 라이너
사우버 클라우스
트리삐에르 도미니크
Original Assignee
하인리히 벡커, 베른하르트 베크
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6355879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR910001041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하인리히 벡커, 베른하르트 베크, 훽스트 아크티엔게젤샤프트 filed Critical 하인리히 벡커, 베른하르트 베크
Publication of KR910001041A publication Critical patent/KR910001041A/ko
Application granted granted Critical
Publication of KR0140884B1 publication Critical patent/KR0140884B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

내용 없음.

Description

지효성의 히루딘 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 하루딘 또는 이의 생리학적으로 허용되는 염 및 담체로 형성된 히루딘 유도체.
  2. 제1항에 있어서, 담체가 다당류인 히루딘 유도체.
  3. 제1항 또는 2항에 있어서, 담체가 덱스트란 또는 헤파린인 히루딘 유도체.
  4. 제1 내지 3항중 어느 한항에 있어서, 담체가 저분자량 헤파린인 히루딘 유도체.
  5. 제1내지 4항중 어느 한 항에 있어서, 히루딘이
    히루딘 유도체.
  6. 제1내지 5항중 어느 한항에 있어서, 히루딘의 Lys 26 및 Lys 35 또는 Lys 35 및 Lys 46 또는 Lys 26 및 Lys 46이 각 경우에 천연 아미노산으로 대체된 히루딘 유도체.
  7. 제1 내지 6항중 어느 한 항에 있어서, 히루딘의 Lys 26이 Asn으로 및 Lys 35 또는 Lys 46이 Arg로 대체된 히루딘 유도체.
  8. 제1 내지 7항중 어느 한 항에 있어서, 히루딘이 N-말단 연장되고 Lys 26, Lys35 및 Lys 46이 다른 천연 아미노산으로 대체된 히루딘 유도체.
  9. 제1내지 8항중 어느 한 항에 있어서, 히루딘이 하나의 천연 아미노산에 의해 C-말단 연장된 히루딘 유도체.
  10. 히루딘을 0℃ 내지 25℃에서 활성화된 담체와 반응시킴을 특징으로 하는 히루딘 유도체의 제조방법.
  11. 제1 내지 9항중 어느 한 항에 청구된 히루딘 유도체의 트롬빈 억제제로서의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890007560A 1988-06-04 1989-06-02 지속적으로 작용하는 히루딘 유도체 KR0140884B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3819079.6 1988-06-04
DE3819079A DE3819079A1 (de) 1988-06-04 1988-06-04 Hirudin-derivate mit verzoegerter wirkung

Publications (2)

Publication Number Publication Date
KR910001041A true KR910001041A (ko) 1991-01-30
KR0140884B1 KR0140884B1 (ko) 1998-06-15

Family

ID=6355879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007560A KR0140884B1 (ko) 1988-06-04 1989-06-02 지속적으로 작용하는 히루딘 유도체

Country Status (21)

Country Link
US (1) US5538946A (ko)
EP (1) EP0345616B1 (ko)
JP (1) JP2804514B2 (ko)
KR (1) KR0140884B1 (ko)
AT (1) ATE130315T1 (ko)
AU (1) AU625215B2 (ko)
CA (1) CA1340197C (ko)
CY (1) CY2025A (ko)
DE (2) DE3819079A1 (ko)
DK (1) DK175103B1 (ko)
ES (1) ES2080732T3 (ko)
FI (1) FI98703C (ko)
GR (1) GR3018364T3 (ko)
HK (1) HK1006024A1 (ko)
HU (1) HU204851B (ko)
IE (1) IE72201B1 (ko)
IL (1) IL90507A0 (ko)
NO (1) NO177312C (ko)
NZ (1) NZ229402A (ko)
PT (1) PT90743B (ko)
ZA (1) ZA894180B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000887A1 (en) * 1988-11-01 1990-05-01 Cecilia S.L. Ku Thromboresistant materials and methods for making same
JP3187044B2 (ja) * 1989-12-01 2001-07-11 ビーエーエスエフ アクチェンゲゼルシャフト ヒルジン突然変異蛋白質及びヒルジンポリアルキレングリコール複合体
JP2975632B2 (ja) * 1990-03-30 1999-11-10 生化学工業株式会社 グリコサミノグリカン修飾プロテイン
GB2247239A (en) * 1990-08-22 1992-02-26 Ciba Geigy Ag Hirudin conjugates with polyoxyethylene
DE4041185A1 (de) * 1990-12-21 1992-06-25 Knoll Ag Verwendung von hirudin und dessen muteinen zur kombinationsbehandlung von tumoren
DE4437502A1 (de) * 1993-12-02 1995-06-08 Basf Ag Hirudin-Konjugate aus Hirudin und lipophilen Verbindungen
DE4342154A1 (de) * 1993-12-10 1995-06-14 Behringwerke Ag Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
DE19533817C2 (de) * 1995-09-13 1999-12-09 Max Planck Gesellschaft Komplex-gebundene Hemmstoffe aktivierbarer Stoffwechselenzyme als molekulare Marker zur Diagnostik und Therapieüberwachung
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US5856452A (en) * 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
DE19915862A1 (de) * 1999-04-08 2000-10-12 Max Planck Gesellschaft Verwendung von molekulargewichtserweitertem Hirudin als Antikoagulans bei der extrakorporalen Nierenersatztherapie
US6809076B2 (en) * 2000-03-20 2004-10-26 Abbott Gmbh & Co. Kg Use of anticoagulant agents in the extracorporeal treatment of blood
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000638A1 (en) * 1978-02-17 1979-09-06 Thin Conductive Coating Oester A method of producing thrombosis-resistant surfaces
DE2930542A1 (de) * 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
CA1341414C (fr) * 1984-03-27 2002-12-31 Paul Tolstoshev Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
DE3438296A1 (de) * 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
EP0168342B1 (de) * 1984-06-14 1991-07-03 Ciba-Geigy Ag Verfahren zur Herstellung von Thrombin-Inhibitoren
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
DE3500268A1 (de) * 1985-01-05 1986-07-10 Hoechst Ag, 6230 Frankfurt Praeparate mit verzoegerter wirkung, verfahren zu deren herstellung sowie entsprechende mittel zur human- bzw. veterinaermedizinischen anwendung
DE3506992A1 (de) * 1985-02-27 1986-08-28 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn Modifizierte hirudine, verfahren zu deren herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten
FR2593518B1 (fr) * 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
DE3689525D1 (de) * 1985-07-17 1994-02-24 Hoechst Ag Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel.
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens

Also Published As

Publication number Publication date
DE58909493D1 (de) 1995-12-21
FI892686A0 (fi) 1989-06-01
ES2080732T3 (es) 1996-02-16
AU625215B2 (en) 1992-07-02
PT90743B (pt) 1994-10-31
HU204851B (en) 1992-02-28
CA1340197C (en) 1998-12-15
EP0345616B1 (de) 1995-11-15
JP2804514B2 (ja) 1998-09-30
IE72201B1 (en) 1997-04-09
HK1006024A1 (en) 1999-02-05
ATE130315T1 (de) 1995-12-15
JPH0267300A (ja) 1990-03-07
NO177312B (no) 1995-05-15
FI98703C (fi) 1997-08-11
CY2025A (en) 1998-02-20
US5538946A (en) 1996-07-23
EP0345616A3 (de) 1991-03-20
PT90743A (pt) 1989-12-29
NO892267D0 (no) 1989-06-02
FI98703B (fi) 1997-04-30
EP0345616A2 (de) 1989-12-13
IL90507A0 (en) 1990-01-18
ZA894180B (en) 1990-02-28
IE891815L (en) 1989-12-04
DE3819079A1 (de) 1989-12-07
DK270789A (da) 1989-12-05
NO892267L (no) 1989-12-05
AU3595589A (en) 1989-12-07
NO177312C (no) 1995-08-23
GR3018364T3 (en) 1996-03-31
DK175103B1 (da) 2004-06-01
KR0140884B1 (ko) 1998-06-15
NZ229402A (en) 1992-05-26
DK270789D0 (da) 1989-06-02
HUT51298A (en) 1990-04-28
FI892686A (fi) 1989-12-05

Similar Documents

Publication Publication Date Title
KR910001041A (ko) 지효성의 히루딘 유도체
EP0340741A3 (en) Polyethylene glycol derivatives, modified peptides and production thereof
KR910016770A (ko) 글리코사미노글리칸-변형된 단백질
DE69632546D1 (de) Ob proteinderivate mit verlängerter halbwertzeit
UA27229C2 (uk) Фракція гіалуронової кислоти або її солі для застосування в офтальмології, спосіб одержання фракції натрієвої солі гіалуронової кислоти та фармацевтичний препарат для використання в офтальмології
ATE130327T1 (de) Polyethylenglykolderivate, modifizierte peptide derselben, ihre herstellung sowie verwendung der modifizierten peptide.
DK0527821T3 (da) Oxidationsresistente thrombomodulinanaloger
DE3486341D1 (de) Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen.
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
KR910016767A (ko) 신규한 펩티드
FI892185A (fi) Menetelmä terapeuttisesti käyttökelpoisten peptidiyhdisteiden valmistamiseksi
ES2081817T3 (es) Polipeptido con secuencias principales repetidas que se fijan en la celula.
IT1209945B (it) Derivati piridinici e procedimenti per la loro preparazione
KR840006328A (ko) 펩티드의 제조방법
EP0241136A3 (en) Human class 1 heparin-binding growth factor
KR900007845A (ko) 에토포시드-2-디메틸아미노 화합물 염산염의 2수염결정 및 그 제조방법
EP0348892A3 (en) Sialic acid-bonded octapeptide and preparation thereof
HUP9601527A2 (hu) Véralvadásgátló hatású peptid-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
DE68908958T2 (de) Peptide.
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
SE8904188D0 (sv) Chromogenic substrate
SE7706567L (sv) Biologiskt aktiva peptider
KR960021058A (ko) B형 간염 백신의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120221

Year of fee payment: 15

EXPY Expiration of term